[Recent progress in study and therapy for COPD].
D000280:Administration, Inhalation; D001993:Bronchodilator Agents / Q000627:therapeutic use; D003577:Cytochrome P-450 Enzyme System / Q000502:physiology; D004851:Epoxide Hydrolases / Q000502:physiology; D005081:Exercise Therapy; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D008562:Membrane Glycoproteins / Q000502:physiology; D018375:Neutrophil Activation; D010102:Oxygen Inhalation Therapy; D010196:Pancreatic Elastase / Q000502:physiology; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D011956:Receptors, Cell Surface / Q000502:physiology; D012121:Respiration, Artificial / Q000379:methods; D012129:Respiratory Function Tests; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D013482:Superoxide Dismutase / Q000502:physiology; D051193:Toll-Like Receptors; D014057:Tomography, X-Ray Computed; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology; D000515:alpha 1-Antitrypsin / Q000502:physiology
D001993:Bronchodilator Agents; D005938:Glucocorticoids; D008562:Membrane Glycoproteins; D010726:Phosphodiesterase Inhibitors; D011956:Receptors, Cell Surface; D051193:Toll-Like Receptors; D014409:Tumor Necrosis Factor-alpha; D000515:alpha 1-Antitrypsin; D003577:Cytochrome P-450 Enzyme System; D013482:Superoxide Dismutase; D004851:Epoxide Hydrolases; D010196:Pancreatic Elastase